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BOTSWANA'S SUCCESS IN BALANCING THE ECONOMICS OF
HIV/AIDS WITH TRIPS OBLIGATIONS
AND HUMAN RIGHTS

Beata Guzik'

"The right of property is the guardian of every other right, and to deprive
a people of this is in fact to deprive them of their liberty.''

I.

Introduction: Botswana Leading Africa in Economics and AIDS

Botswana serves as a model for Africa and developing countries worldwide.
Due to its groundbreaking response to HIV/AIDS, Botswana is a model of access
to medical treatment in Southern Africa. 2 Botswana is the first African country

to aim toward providing antiretroviral therapy to all disadvantaged citizens. It
has enjoyed peace since its independence in 1966, and has become relatively
prosperous, 3 with a per capita income of $11,200 in 2006.4 Much of Botswana's
success is due to diamond mining (accounting for more than one-third of its
GDP), but other key sectors include tourism, financial services, farming, and cattle. 5 With an estimated 2006 GDP of nearly $19 billion, the Central Intelligence
6
Agency ("CIA") ranks Botswana 120 out of 229 world economies.
Despite such economic success, Botswana battles against HIV/AIDS. 7 With
24.1% of its population infected, Botswana has the second highest adult HIV/
t
Beata Guzik is a Juris Doctor candidate at Loyola University Chicago School of Law, 2008.
She extends her special thanks to her family and friends for their continued support in helping her attain
her goals.
I Arthur Lee, An Appeal to the Justice and Interests of the People of Great Britain, in the Present
Dispute with America, (4th ed. 1775), available at Citizens' Alliance for Property Rights, http://www.
proprights.org (last visited Apr. 1, 2007).
2 3D Three, Trade-Related Intellectual Property Rights, Trade in Services and the Fulfillment of
Children's Rights-Botswana
1 (Sept. 2004), http://www.3dthree.org/pdf_3D/3DCRCBotswana
Sept04en.pdf [hereinafter Trade and Children's Rights].
3 Avert, HIV and AIDS in Botswana, http://avert.org/aidsbotswana.htm (last visited April 28, 2007)
[hereinafter AIDS In Botswana].
4 The World Factbook, Botswana, CIA, https://www.cia.gov/cia/publications/factbook/goes/bc.html
[hereinafter CIA Factbook].
5 Id.
6 The World Factbook, Rank Order-GDP(purchasing power parity), CIA, https://www.cia.gov/
cia/publications/factbook/rankorder/200 1rank.html. Actual 2006 GDP estimate is $18.72 billion. Id.
7 "The United Nations has characterized the impact of the HIV/AIDS crisis in Africa as 'no less
destructive than that of warfare itself."' Lissett Ferreira, Access to Affordable HIV/AIDS Drugs: The
Human Rights Obligations of Multinational PharmaceuticalCorporations,71 FORDHAm L. Rav. 1133,
1133 (2002) (quoting Press Release, United Nations, In Address to Security Council, Secretary-General
Says Fight against AIDS in Africa Immediate Priority in Global Effort against Disease, SG/SM/7275
AFR/200 SC/6780 (Jan. 6, 2000)).
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AIDS rate in the world. 8 Human rights and health concerns, therefore, must be
balanced against economic interests in policy making.
Botswana attempts to address both human rights and economic concerns as a
signatory to the Convention on the Rights of the Child ("CRC"), the World Trade
Organization Intellectual Property Agreements ("TRIPS"), and the General
Agreement on Trade in Services ("GATS"). Human rights groups fear that the
resulting obligations conflict with one another, and may hinder the nation's ability to fight the HIV/AIDS epidemic. 9 One worry is that the TRIPS-mandated
twenty year exclusivity rights for the developer of patented technology will artificially drive up prices of pharmaceuticals, making them unaffordable for many of
Botswana's citizens. 10 Unaffordable medications directly conflict with the country's obligation under the CRC to protect the life, health, survival, and development of the nation's children.'"
While preserving human rights, Botswana must deal with the seemingly conflicting need of ensuring economic growth. Economic growth and prosperity2
from diamond mining helps Botswana fight against the HIV/AIDS epidemic.'
Economists agree that innovation plays a pivotal role in continued economic
growth and development. 13 "Over the past half century, researchers beginning
with Nobel Laureate Robert Solow have established that the development and
adoption of economic innovation is the most powerful factor determining a nation's underlying growth rate."1 4 Moreover, strong intellectual property laws encourage technology transfers and investments by foreign countries.' 5 For
8 AIDS in Botswana, supra note 3 at 1. In 2005, there were an estimated 270,000 people living
with HIV in Botswana; the total population is about 2 million people. Id. Botswana has accepted a
prevalence rate of 17.1 %, based on people aged eighteen months and above reported to be HIV positive
in 2004. 2005 ProgressReport of the National Response to the UNGASS Declarationof Commitment on
HIV/AIDS, Ministry of State President, § 2.2. [hereinafter 2005 Report]. The estimate rises drastically,
however, when compared to individuals 15-49 years old, 25.3% of whom were living with AIDS in
2004. Id. Additional statistics are frightening. Life expectancy at birth from 2000-2005 is less than
forty years and 120,000 children have lost at least one parent to AIDS. AIDS in Botswana, supra note 3.
The Impact of Aids, United Nations, 2004.
9 See Trade and Children's Rights, supra note 2,

3-5.

10 See id., [8. In 2003, 30.3% of Botswana's population fell below the poverty line. CIA Factbook,

supra note 4.
11 See Trade and Children's Rights, supra note 2, 8.
12 See CIA Factbook, supra note 4.
13 Robert J. Shapiro & Kevin A. Hasset, The Economic Value of IntellectualProperty, 6, (Oct. 2005),
http://www.usaforinnovation.org/news/ip-master.pdf. "In the United States, the world's most successful
advanced economy, an estimated 30 percent to 40 percent of the gains in productivity and growth
achieved during the 20th century are attributable to economic innovation in its various forms." Id. Of
the gains in the growth rate of U.S. productivity from 1995-2001, the development of new information
technologies accounted for 28% of gains, capital investment in those technologies for 34%, research and
development for 10% and response by firms in the areas of organization and worker training in response
to innovation accounted for another 10%. Id. at 7.
14 Id. at 6.
15 Id. at 13. The strength of intellectual property protection sends an important signal to would-be
investors: "It is likely that potential investors perceive the adequacy of the [intellectual property rights]
regime as an indication of the government's attitude towards foreign direct investment . . ." Simon
Helm, Intellectual Property In Transition Economies: Assessing the Latvian Experience, 14 FORDHAM
INTELL. PROP. MEDIA & ENT. L.J. 119, 132 (2003) (quoting Beata Smarzynska, Composition of Foreign
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example, for every 1% increase in the degree of patent protection in a developing
country, United States based investment in that country expands by .45%.16
Property rights protection also encourages multinational firms to shift research
and development activity to developing countries, creating a virtuous cycle as
technology is transferred and adopted by domestic citizens and firms, and the
domestic rate of intellectual property development increases.' 7 Additional encouragement is provided for pharmaceutical firms to begin research and development of medicines necessary to fight the specific medical afflictions of each
region.18 This demonstrates "that greater respect for intellectual property rights
can be literally a matter of life and death in many developing countries." 19
For Botswana to continue to grow and prosper it must fulfill its obligations in
fighting the HIV/AIDS epidemic while ensuring that innovation is encouraged
through the protection of intellectual property rights. 20 This article will examine
whether such obligations are truly inconsistent, and suggests that both aims may
be met through already existing compromises. Part II of this paper discusses the
CRC and corresponding obligations. Part III explores the Agreement on Trade
Related Intellectual Property Rights ("TRIPS") and the agreement's effect on
drug availability and affordability. Part IV examines how Botswana worked to
fulfill its obligations under both of these international agreements. Finally, Part
V concludes that these obligations can be fulfilled in a manner consistent with
both treaties, and that Botswana may, in the future, pave the way to combating
the HIV/AIDS epidemic in Africa.
II. Convention on the Rights of the Child: Life Saving Medicines for the
Whole Family
The CRC entitles all children to basic human rights protections and is considered by many as "the most rapidly and universally accepted human rights document in the history of international law."'2' The CRC represents the first binding
international human rights instrument to incorporate civil, political, economic,
social, and cultural rights while managing to provide each priority with equal

Direct Investment and Protection of Intellectual Property Rights in Transition Economies 2 (Center for
Economic Policy Research, Discussion Paper No. 2228, 1999)).
16 Id.

17 Shapiro & Hasset, supra note 13, at 15-16.
18 Id. at 16. One study found an increase in local research of anti-malaria drugs by pharmaceutical
companies as a result of improved IP protection in areas prone to malaria outbreaks. Id.
19 Id.

20 See id. at 5-6.
21 Lauren M. Spitz, Implementing the U.N. Convention on the Rights of the Child: Children'sRights
under the 1996 South African Constitution, 38 VAND. J. TRANSNAF'L L. 853, 854 (2005) (quoting Barbara Bennett Woodhouse, Recognizing Children's Rights: Lessons from South Africa, 26 SPG HUM.
RTS. 15, 15 (1999)).
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emphasis. 22 2 Article
6 awards children the most basic of all human rights: the
3
right to life.
The right to life facially creates an obligation to prevent death and illness, but
some have suggested a broader interpretation.2 4 Article 6 of the CRC states that
each signatory must "ensure to the maximum extent possible the survival and
development of the child. '25 Article 24 of the CRC creates an affirmative right
to the "highest attainable standard of health. '26 According to the U.N. Commission on Human Rights, access to HIV/AIDS medication is "one fundamental element for achieving progressively the full realization of the right of everyone to
27
the enjoyment of the highest attainable standard of physical and mental health.
Perhaps these obligations can be read to protect the child's entire family unit
from the ravaging effects of HIV/AIDS. In sub-Saharan Africa, 9% of all children under the age of fifteen have lost at least one parent to the disease. 28 The
results for these children are heartbreaking. They suffer from psychological
trauma, poverty, social dislocation, and often, discrimination. 29 Education is significantly affected, as orphans are 13% less likely to attend school than nonorphans. 30 Demands on public sector services such as health care and education
31
also begin to increase as the adult population wanes.
"Botswana lost approximately 17% of its health-care workforce due to AIDS
between 1999 and 2005."32 The loss created an obstacle as Botswana continues
to work to provide antiretroviral therapy to all of its citizens. 33 In deciding
whether to make investments, Botswana's business community also takes the
loss into account, as Botswana projects that 23% of its agricultural labor force
alone will be lost by the year 2020. 34 The children of families with HIV/AIDS,
lacking resources such as education and stability, face many difficulties in attempting to fill the gaps their parents leave behind. 35 Any failure in fighting the
HIV/AIDS epidemic, therefore, is a failure to protect the right to both the physi22 Id. at 866.

23 M.E. Klinck, B. luris, D.A. Louw & B.J. Peens, A South African Perspective on Children's Rights:
Pertinent Issues In Remedial and Protection Interventions, 19 MED. & L. 253, 254 (2000).
24 Id. at 254.

25 Id.
26 Id. at 256.

27 Access to Medication in the Context of Pandemics such as HIV/AIDS, Hum. Rts. Comm'n Res.
2003/29, U.N. ESCOR, 57th Sess., Supp. No. 3, 56th mtg. U.N. E/CN.4/2003/L. 11/Add.3 (Apr. 22,
2003).
28 UNAIDS, 2006 Report on the Global AIDS Epidemic, Chapter 4 at 92, http://www.unaids.org/en/
HIV_data/2006GlobalReport/default.asp [hereinafter UNAIDS Impact].
29 Id. at 91.

30 Id. at 92.
31 Id.

32 Id. at 95.

33 World Health Organization, Summary Country Profile for HIVIAIDS Treatment Scale-Up: Botswana (Dec. 2005), http://www.who.int/hiv/HIVCP_-BWA.pdf [hereinafter WHO Treatment].
34 UNAIDS Impact, supra note 28, at 98, 100.
35 See generally UNAIDS Impact, supra note 28.
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cal and productive life of the nation's children. The future stability of
Botswana
6
after-effects.3
its
and
HIV/AIDS
both
of
stabilization
depends upon
III.

TRIPS, Compulsory Licenses, and the Delivery of Medication

As a signatory to the TRIPS agreement, 37 Botswana is required to provide
minimum standards for intellectual property protection. 38 Botswana officially
notified the World Trade Organization ("WTO") of its compliance in June
2001. 39 In reaching compliance, the country incorporated many of TRIPS flexibilities into its intellectual property laws. 40 It made use of compulsory licensing
and government use measures, and excluded from patentability "diagnostic, therapeutic and surgical methods for the treatment of humans."'4' As a result, HIV/
kits cannot be patented in Botswana and are therefore available
AIDS diagnostic
42
at low cost.
TRIPS reoriented intellectual property protection as an international issue
(rather than a purely national issue), setting minimum enforceable international
standards. 43 From the outset, TRIPS represented the tension existing between the
need to protect pharmaceutical patents, and the need to protect public health
through access to medicines. 44 TRIPS aims to ensure that "protection and enforcement of intellectual property rights should contribute to the promotion of
technological innovation ... in a manner conducive to social and economic welfare, and to a balance of rights and obligations. '45 Thus, the agreement intends
to enhance both economic and social welfare by protecting intellectual property,
46
which should in turn contribute to innovation and the transfer of technology.
36

See id.

37 General Agreement on Tariffs and Trade-Multilateral Trade Negotiations (The Uruguay Round):

Agreement on Trade-Related Aspects of Intellectual Property Rights, Including Trade in Counterfeit
Goods, Dec. 15, 1993, 33 I.L.M. 81 [hereinafter TRIPS].
38 Trade and Children's Rights, supra note 2, $ 9.
39 Id.
40

Id.

41

Id. (citing Botswana, Industrial Property Act, 1996, §§ 30-31, 69.)

Id. (citing Botswana, Industrial Property Act, 1996, § 9(f), as amended by Industrial Property
(Amendment Act), 1997.)
42

43 See Srividhya Ragavan, The Jekyll and Hyde Story of InternationalTrade: The Supreme Court in
PhRMA v. Walsh and the TRIPS Agreement, 38 U. RICH. L. REV. 777, 777-78 (2004). See also TRIPS,
supra note 37, arts. 15-18.
44 See Peggy B. Sherman & Ellwood F. Oakley, III, Pandemics and Panaceas: The World Trade
Organization'sEfforts to Balance PharmaceuticalPatents and Access to Aids Drugs, 41 AM. Bus. L. J.
353, 363 (2004). See also World Trade Organization, Understanding the WTO: The Agreements: Protection and Enforcement, available at http://www.wto.org/english/thewto-e/whatise/ tif_e/agrm7_e.htm
(last visited Apr. 18, 2007) [hereinafter TRIPS Explanation]. "The extent of protection and enforcement
of these rights varied widely around the world; and as intellectual property became more important in
trade, these differences became a source of tension in international economic relations." Id.
45 TRIPS, supra note 37, § 1, art. 7.
46 Trips Explanation, supra note 44.

Volume 4, Issue 2

Loyola University Chicago International Law Review

259

Botswana's Success with TRIPS and Human Rights

users of pharmaceuticals should enjoy the benefits
Therefore, both producers and
47
development.
of increased
This balance is the result of a compromise between the desire of developed
countries to obtain strong global intellectual property protection, and the resistance of the developing world to any standards of protection. 48 Some developing
nations argue that conforming their patent laws to those of developed nations
causes the price of medication to rise too high for their citizens to afford.4 9 On
the other hand, many developed nations contend that uniform international laws
promote free and balanced trade, the maintenance of a healthy economy, and the
development of new medicines. 50 TRIPS is a result of a compromise between
the two, in which developed countries received minimum intellectual property
protections in exchange for improvements in agricultural and textile trade positions for the developing countries. 5 1 Additionally, TRIPS allowed flexibility for
developing nations, including the "exclusion of certain items from patentability,
compulsory licensing under certain conditions, parallel importation, and technical
cooperation in favor of developing and least-developed member
and financial
52
states."
Two of the main objectives of TRIPS are to promote "social and economic
54
welfare," 5 3 and a "reciprocal balance of exchange that yields net benefit to all."
Intellectual property protection benefits all participating countries, as an enhancement in such laws is analogous to removing trade barriers such as tariffs. 55 Such
protection encourages investment, and allows artists and investors to remain
56
within their own countries because they can be compensated for their work. It
also ensures continued incentives for pharmaceutical companies to fight specialized diseases in developing areas of the world because any newly developed
57
medicines are subject to patents.
47 Id.

48 Sherman & Oakley, supra note 44, at 362.
49 Jessica J. Fayerman, The Spirit of TRIPS and The Importationof Medicines Made Under Compulsory License After the August 2003 TRIPS Council Agreement, 25 Nw. J. INT'L L. & Bus. 257, 257
(2004).
50 Id.
51 See Sherman & Oakley, supra note 44, at 362. See also Jose E. Alvareaz & Joel Trachtman,
Institutional Linkage: Transcending Trade, 96 AM. J. INT'L L. 77, 78-79 (2002). TRIPS attempts to
address the shortcomings of earlier treaties including the Paris Convention, Berne Convention, and
Washington Treaty. Michelle M. Nerozzi, The Battle Over Life-Saving Pharmaceuticals: Are Developing Countries Being TRIPed by Developed Countries? 47 VILL. L. Rev. 605, 611 (2002). Two weaknesses experienced by the Paris Convention were the lack of harmonized international patent laws, and
the lack of enforcement provisions. Id. at 611-12. TRIPS was created to alleviate some of these
problems while addressing the concerns of developing members. Id. at 612.
52 Nerozzi, supra note 51, at 612.
53 TRIPS, supra note 37, art. 7.
54 Ragavan, supra note 43, at 779-80 (quoting Alan 0. Sykes, TRIPS, Pharmaceuticals,Developing
Countries, and the Doha "Solution," 3 CHI. J INT'L L. 47, 60 (2002).)
55 Fayerman, supra note 49, at 268.
56 Id.
57 Id.
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Furthermore, developing nations carry a high cost in prioritizing trade interests
(often to the detriment of welfare), referred to as the "poverty penalty." 58 As a
result of TRIPS, countries must prioritize international obligations to avoid trade
sanctions.5 9 Such prioritization, however, affects the ability of signatories to fulfill national obligations. 60 At issue is the use of compulsory licensing and price
control mechanisms, often utilized by developing nations to increase access to
6
medication by the population. '
A.

Patent Protection and the Public Health Exception

TRIPS extends patent protection to pharmaceuticals pursuant to Article 27.62
Patent protection is offered for a minimum of twenty years from the date of the
filing of the patent application. 6 3 The patent holder has the exclusive rights to
make, use, offer for sale, assign or transfer the patent, and to enter into licensing
contracts-creating value for the patent holder. 64 Such protections, however,
"can affect access to affordable medicines, which is a crucial element of fulfilling
'65
the child's right to health and the right to life, survival and development.
66
While the patent holder's rights are broad, they are not without exception.
Before 1995, many developing countries did not recognize patent protection for
pharmaceuticals. 67 Piracy, parallel importing, and the generic production of patented pharmaceuticals were common problems. 68 Patent protection aims to rem58 Ragavan, supra note 43, at 779. The term "poverty penalty" refers to the cost born by developing
nations in implementing international agreements that require prioritizing trade responsibilities to the
detriment of sovereign welfare. Id. The poorer nations suffer a loss where they do not have the resources
that allow developed nations to resort to price controls and compulsory licenses in times of crises. Id. at
779-80.
59 Id. at 778. See also TRIPS, supra note 37, arts. 41-50. TRIPS includes mandatory enforcement
provisions. Id.
60 Ragavan, supra note 43, at 778.
61 Id. Patrick Marc, Compulsory Licensing and the South African Medicine Act of 1997: Violation
or Compliance of the Trade Related Aspects of IntellectualProperty Rights Agreement?, 21 N.Y.L. SCH.
J. INTr'L & COMP. L. 109, 121-22 (2001).
62 Sherman & Oakley, supra note 44, at 363; TRIPS, supra note 37, art. 27. Patent protection is
made clear through a cross-reference to Article 70(8). Sherman and Oakley, supra note 44, at 363.
63 TRIPS, supra note 37, § 5, art. 33; TRIPS Explanation, supra note 44.
64 TRIPS, supra note 37, § 5, art. 28. "1. A patent shall confer on its owner the following exclusive
rights: (a) where the subject matter of a patent is a product, to prevent third parties not having [the
owner's] consent from the acts of: making, using, offering for sale, selling, or importing for these purposes that product... ; (b) where the subject matter of a patent is a process, to prevent third parties not
having [the owner's] consent from the act of using the process, and from the acts of: using, offering for
sale, selling, or importing for these purposes at least the product obtained directly by that process. 2.
Patent owners shall also have the right to assign, or transfer by succession, the patent and to conclude
licensing contracts." TRIPS, supra note 37, § 5, art. 28.
65 Trade and Children's Rights, supra note 2, 8.
66 Sherman & Oakley, supra note 44, at 365.
67 Id.

at 363.

68 Id. Parallel importation results in a "grey market" where medicines sold at lower prices in less
developed countries are sold in wealthier countries at below market prices. Fayerman, supra note 49, at
271-72.
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edy such dilemmas while allowing governments room to protect the public
69
health.
70
Article 27 of the TRIPS agreement contains two public health exceptions.
First, members may exclude from patentability inventions when exclusion is necessary for the public order or morality, including for the protection of human life
or health. 7 1 Ambiguity in this provision led some to argue that HIV/AIDS drugs
should not be subject to TRIPS because they are necessary to protect the public
health. 72 In contrast, others argue that the exception simply excludes dangerous
73
products from patentability.
Second, an exception exists for the "diagnostic, therapeutic and surgical methods for the treatment of humans. '74 Ethical reasons and the difficulty of enforcement, however, resulted in few countries granting such patents. 75 Methods used
directly on humans also do not generally avail themselves to patentability because "a method that is applied to the human body is not considered industrially
applicable and so does not comply with one of the key patentability requirements
of most patent laws."'76 In the rare circumstances where such patents are offered,
77
they negatively affect the ability of low-income patients to access treatments.
This is true in areas such as gene-therapy,7 8 and may have more of an effect on
HIV/AIDS patients as advances in medicine continue.
B.

Compulsory Licenses, Circumventing the Patent?

In striking a balance between the needs of patent holders and poor nations,
TRIPS includes allowances for provisions such as compulsory licenses to ensure
that developing countries will gain access to life saving medicines. 79 It also
makes technology building in least developed countries a goal, so the need for
compulsory licenses is diminished over time.8 0
"A patent is a grant issued by a national government conferring the right to
exclude others from making, using, or selling the invention within the national
territory." 8 1 Patents represent a compromise between the public interest and the
69 See Sherman & Oakley, supra note 44, at 362; TRIPS, supra note 37, art. 7.

70 TRIPS, supra note 37, § 5, art. 27(2).
71 Id.
72 Fayerman, supra note 49, at 260.
73 Id.

74 TRIPS, supra note 37, § 5, art. 27(3).
75 Carlos M. Correa, Public Health and Patent Legislation inDeveloping Countries, 3 TUL. J. TECH.
& INTELL. PROP. 1, 16. (2001).
76 Id.
77 Id.at 17.
78 Id.
79 Fayerman, supra note 49, at 269.
80 Id.
81 Ferreira, supra note 7, at 1138, (quoting INTERNATIONA-

INTELLECTUAL PROPERTY LAW 3

(Anthony D'Amato & Doris Estelle Long eds., 1997)).
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patentee's absolute property rights over the invention. 82 This compromise strikes
a balance between the patentee's ability to seek maximum compensation and
society's need for the product. 83 This limited monopoly provides an incentive
84
for pharmaceutical companies to invest in, research, and produce new drugs.
In contrast, compulsory licenses are an involuntary contract between a willing
buyer, the government, and an unwilling seller, the patentee. 85 Such contracts
affect market exclusivity directly, and market price indirectly, through the use of
price controls.8 6 "Direct price control is where the government restricts the market price of a product from exceeding a certain percentage above the cost of
production. Indirect price control is where the government uses an incentive, a
deterrent, or both to prevent the manufacturer from realizing the highest marginal
87
profit."1
The demand for pharmaceuticals, however, is inelastic, and it produces different results in both low and high per capita income-earning countries. In low per
capita areas, the result is the need to resort to tools such as compulsory licensing. 88 This is because increasing the cost reduces affordability in the short run,
but increases demand for the drugs as diseases worsen. 8 9
However, for patents to cause an effect on drug prices, patents must first be
secured. 90 "Patents have to be secured on a country-by-country basis." 9 1 If a
particular country has not granted some form of protection, then its residents
cannot be sued for copying the product, importing copies, or parallel importation. 92 Therefore, patents alone can not be responsible for limited access to
medications because most of Africa does not have patented medicine. 9 3 The
Journal of the American Medical Association reported in 2001 that only 21% of
antiretrovirals were patented in African countries. 94 This study, however, has
82 Ragavan, supra note 43, at 782. Rafael V. Baca, Compulsory Patent Licensing in Mexico in the
1990's: The Aftermath of NAFTA and the 1991 Industrial Property Law, 35 IDEA 183, 184 (1994).
Compulsory licenses allow governments "to compensate for the economic shortcomings associated with
not establishing a domestic industrial base when not working an invention within its borders." Id. at 187.
83 Ragavan, supra note 43, at 782.
84 Ferreira, supra note 7, at 1138.
85 Sara M. Ford, Compulsory Licensing Provisions Under the TRIPS Agreement: Balancing Pills
and Patents, 15 AM. U. INT'L L. REV. 941, 945 (2000) ("Compulsory licensing is defined generally as the

granting of a license by a government to use a patent without the patent-holders permission"). Gianna
Julian-Arnold, InternationalCompulsory Licensing: The Rationales and the Reality, 33 IDEA 349, 349
(1993).
86 Ragavan, supra note 43, at 782.
87 Id. at 782-83.
88 Id. at 783.
89 Id.

90 Simon Barber, Finance,not patents, bars AIDS treatment in Africa, Business Day: South Africa,
Center for International Development at Harvard University, (Oct. 17, 2001), available at http://www.
cid.harvard.edu/cidinthenews/articles/SABusiness-Day-101701 .html.
91 Id.
92 Id.
93 Id.

94 Id. (average over all African countries).

Volume 4, Issue 2

Loyola University Chicago International Law Review

263

Botswana's Success with TRIPS and Human Rights
been criticized for its omission of crucial drugs and the lack of consideration of
the effects of patents on new drug combinations of older drugs. 9 5
Where patents are secured in the international forum, TRIPS ensured access to
medication through flexibilities written into the document. 96 Article 31 leaves
open the possibility of using compulsory licenses although it does not refer to
them per se. 97 The language, however, is sufficiently ambiguous such that it is
read differently by developed and developing countries: "[w]ithout terming it
such, TRIPS allows for compulsory licensing amidst several provisions in Article
31 ."98
Article 31 specifically limits the exportation of medicines under compulsory
licenses outside the country that issued the license. 99 Drug companies often sell
their drugs at varying prices in different countries, while each country offers
varying degrees of patent protection.'°0 When a government imports a patented
drug from a country where it is sold at a discount, the practice is dubbed parallel
importation. 101
To begin manufacturing under a compulsory license, the government must
first make reasonable attempts to seek permission of the patent owner.' 0 2 This
requirement is waived under a national emergency, and the government has discretion in determining whether public health concerns outweigh the urgency of
international intellectual property protections. 0 3 However, the government's use
95 Ferreira, supra note 7, at 1139.
96 TRIPS Explanation, supra note 44.
97 Fayerman, supra note 49, at 258. Article 31 provides "Where the law of a Member allows for
other use of the subject matter of a patent without the authorization of the right holder... such use may
only be permitted if, prior to such use, the proposed user has made efforts to obtain authorization from
the right holder on reasonable commercial terms and conditions and that such efforts have not been
successful within a reasonable period of time. TRIPS, supra note 37, § 1, art. 31. This requirement may
be waived by a Member in the case of a national emergency or other circumstances of extreme urgency
or in cases of public non-commercial use..." It also provides that members are not obligated to abide by
these conditions "where such use is permitted to remedy a practice determined after judicial or administrative process to be anti-competitive." Id.
98 Nerozzi, supra note 51, at 613 (quoting Sara M. Ford, Note & Comments, Compulsory Licensing
Provisions under the TRIPS Agreement: Balancing Pills and Patents, 15 AM. U. INT'L L. RaV. 941, 949
(2000)); See also Robert Weissman, A Long, Strange TRIPS: The PharmaceuticalIndustry Drive to
Harmonize Global Intellectual Property Rules, and the Remaining WTO Legal Alternatives Available to
Third World Countries, 17 U. PA. J. INT'L EcON. L. 1069, 1115 (1996) (suggesting that Article 31
authorizes the use of compulsory licensing while also creating obstacles to such programs).
99 Fayerman, supra note 49, at 262.
100 Ferreira, supra note 7, at 1140.
101 Id.

102 Fayerman, supra note 49, at 260. See also TRIPS, supra note 37, § 5, art. 31(b) ("such use may
only be permitted if, prior to such use, the proposed user has made efforts to obtain authorization from
the right holder on reasonable commercial terms and conditions and that such efforts have not been
successful within a reasonable period of time.")
103 Fayerman, supra note 49, at 262 (clarification made to TRIPS in 2001 at WTO meeting in Doha,
Qatar, stating that AIDS and malaria would be adequate grounds for declaring a national emergency).
See World Trade Organization Ministerial Declaration on the TRIPS Agreement and Public Health of 14
November 2001, WT/M1N(01 )/DEC/2 (Nov. 20, 2001), available at http://www.wto.org/English/thewto
_e/minist-e/min0le/mindecl-tripse.htm.
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1 4
is constrained, while the patent holder is protected with several measures. 0
Countries may not export compulsory licensed products, the patent holder must
be adequately compensated, and use is non-exclusive, non-assignable and subject
05
to judicial review. 1

Compulsory licenses would thus be made unreachable to countries with no
manufacturing base. 10 6 However, the WTO rectified this problem by ensuring
flexibility within the agreement. 10 7 Under TRIPS, countries can export
medicines to an "eligible importing member," but only in a limited way designed
to limit a "grey market" or parallel importation. 0 8 The importing country must
state the name and expected quantity of the drug it wishes to use, must present
evidence that it lacks the requisite manufacturing capacity, must comport with
the compulsory license requirements of Article 31, and must remunerate the exporting country. 10 9 Exporting countries must limit the amount of drugs shipped
and label the product with special colors and shapes. I0 All WTO members are
required to provide legal means by which to limit illegal importation, and all
members are encouraged to transfer needed technology."'I
The flexibilities built into TRIPS enable Botswana to gain access to needed
medications in the short term. To ensure continued economic success, however,
Botswana must guard against too much dependence on outside assistance to combat the HIV/AIDS crises within its own borders. 1 2 As more knowledge is
gained about the HIV/AIDS virus, perhaps Botswana would find it beneficial to
combat the disease from its own unique perspective. 1 3 Botswana faces unique
benefits in its economic success and already existing HIV/AIDS programs, but
receives less and less outside aid, which threatens to stall this fledgling economy.
To encourage development of such specialized products, pharmaceutical companies require incentives and the assurance they will receive remuneration for their
developments. 14 "Some authors in favor of compulsory licensing seem to forget
that without intellectual property protection there would be no medicine at all for
15
the country to license."' '

104 Fayerman, supra note 49, at 260-61; See also TRIPS, supra note 37, § 5, art. 31.
105

Id.

106

Fayerman, supra note 49, at 262.

107

Id.

108 Id.at 263.
109 Id.at 263-64.
110 Id.at 263.
II' Id.
112 Id. at 270.
113 Id.

114Id.
115 Id.
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IV.

The Way Ahead: Treatment and Economy

In fulfillment of the CRC, Botswana took considerable steps in fighting HIV/
AIDS through its landmark national antiretroviral therapy program. 1 6 Since
2001, Botswana provided free drugs to pregnant women with HIV/AIDS, all HIV
positive children less than twelve-months old, and children with AIDS symptoms.1 17 As of October 2005, 55,829 people were reported as receiving antiretroviral treatment." 18 However, in the same year, 110,000 people were reported
to need such treatment.' 19 Of those receiving treatment, 85% received it free of
charge from the public sector, while only 15% receiving funding through the
private sector. 120 Botswana receives funding from multiple sources including
international NGOs, the U.S. government, pharmaceutical manufacturers, and
other agencies. 121
Challenges to increasing the scope of Botswana's antiretroviral program include shortages in government staffing, the need to decentralize, and the need to
involve private practitioners in continuing patient treatment. 122 Staffing
shortages resulted from a government hiring freeze to prevent future budget deficits, as much of the country's monetary resources for antiretroviral treatment
come from outside. 123 The Bill and Melinda Gates Foundation, together with
U.S. drug maker Merck, provided antiretrovirals to every citizen in need. 124 Positive results are shown in the number of AIDS-related deaths, falling from 33,000
in 2003 to 18,000 in 2005.125 Cooperation with international pharmaceutical
manufacturers, therefore, is imperative in aiding Botswana's continued struggle
against HIV/AIDS.
Despite the successful implementation of HIV/AIDS prevention and treatment
programs and generous outside donations, Botswana faces a lot of pressure from
constraints on its economic resources. 126 In 2005, the government spent about
116 See Trade and Children's Rights, supra note 2, 6.
117 Id. Since the antiretroviral therapy program was implemented in January of 2002 at the Princess
Marina Referral Hospital in Gabarone, the number of people being treated has increased steadily. WHO
Treatment, supra note 33. In 2005 there were thirty-two public sites available within at least one of each
of the country's twenty-four health districts. Id.
118 WHO Treatment, supra note 33.
119 Id.
120 Id.
121 Id.
122 Id.

123 Id. Funding has come from the Bill & Melinda Gates Foundation ($50 million over five years),
pharmaceutical manufacturer Merck & Co., Inc. (matching the Gates Foundation), the United States
President's Emergency Plan for AIDS Relief ($24.4 million in 2004 to support prevention, and close to
$51 million in 2005 to combat AIDS), the Global Fund to Fight AIDS, Tuberculosis and Malaria ($18.6
million), and other agencies. Id.
124 Joseph Hall, Canada Breaks AIDS Pledge; Africa Still Waiting for Life-Saving Drugs Two Years
After Ottawa Passed 'Breakthrough Law,' TORONTO STAR, (Aug. 3, 2006), available at http://www.
accessmed-msf.org/prod/publications.asp?scntid=11820061738348&contenttype=& [hereinafter Canada

Breaks Pledge].
125 Id.
126 See 2005 Report, supra note 8,
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$165 million in HIV/AIDS-related expenditures (excluding recurrent indirect
costs such as development of infrastructure, drug procurement, training costs,
hospital budgets, and others). 127 Recently, many donor agencies started to shift
their focus on poorer nations as Botswana is now classified as an upper-middle
28
class country. 1
Criticisms aside, TRIPS may help to save developing countries such as Botswana. Article 7 of the agreement "calls for international intellectual property
protection to be instituted 'in a manner conducive to social and economic wel29 Therefore, TRIPS calls on the international community to give a helpfare.' ,,"
ing hand to nations faced with both the devastating HIV/AIDS crises and limited
resources, which would ensure far more success than the mere use of compulsory
licenses. 130 By encouraging technology investment both domestically and internationally, the TRIPS agreement widens the scope of prospective pharmaceutical
3
development. ' '
Viable alternatives to compulsory licenses may also be utilized. These measures include bulk procurement, voluntary donation, and publicly funded research and development schemes.' 32 Bulk procurement involves a group of
developing countries pooling its resources to obtain large quantities of needed
drugs.' 3 3 This method results in regional cooperation and innovation while guaranteeing high demand, reliable payment, straightforward pricing-negotiations,
and overall pharmaceutical profits in the developing world. 134 Voluntary donations by wealthy countries of excess drug supplies have been successful in both
Haiti and India. 135 Such schemes, however, risk large fluctuations in supply, and
36
do not further the goal of promoting technology transfers and investment.
Publicly funded research projects resulted in improved nutrition in agriculture,
37
but again relied on wealthier donations and non-governmental organizations. 1
While Botswana has been highly successful in implementing its ARV program, the financial cost is staggering.1 38 In 2003, the drugs alone cost the gov127 Id. The country's office exchange rate GDP in 2006 is estimated at approximately $9.7 billion;
despite positive growth rates, HIV/AIDS and an expected leveling off in diamond mining production
threatens long-term economic growth. CIA Factbook, supra note 4.
128 See 2005 Report, supra note 8, 4.2.
129 Fayerman, supra note 49, at 269.
130 Id.

131 Id. at 268.
132 Id. at 272-74.
133 Id. at 273.

134 Id. Critics of the bulk procurement method often point to the fact that the poorest nations may not
be able to afford medicines even on such a large scale. Id. at 274. As an upper-middle class country,
Botswana can utilize its position without this setback. 2005 Report, supra note 8, 4.2.
135

Id. at 273.

136

Id.

137 Id. at 274.
138 U.N. Office for the Coordination of Humanitarian Affairs, Botswana: More than Money Needed
for Successful AIDS Programme (Aug. 4, 2003), http://www.irinnews.org/report.aspx?reportid=45306
(listing the costs of drugs, clinics, and equipment per year, per patient).
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emnment between $1,200 and $3,000 a year per patient; the price jumps to
between $7,000 and $10,000 a year per patient when the price of clinics and
equipment is included. 139 Much of this success, therefore, can be attributed to
the fact that Botswana's market-led economy is among the freest economies in
the world. 140 Current laws serve to encourage investment, and an independent
judiciary provides a sufficient framework for conducting secure commercial
dealings. 14 1 However, obstacles remain for investors, as a backlog of cases is
increasingly preventing investors from obtaining timely trials. 142 An additional
problem exists in the fact that starting a business in Botswana takes 108 days
compared to the world average of only forty-eight days. 143
Further obstacles could arise if the flexibilities of TRIPS are undermined. For
example, currently the United States is quietly entering into bilateral and regional
trade agreements around the world. 144 The United States signed and ratified the
TRIPS agreement "in order to create a broader framework for regulating world
trade."' 145 However, the agreement is non-self-executing which gives it no force
in U.S. courts. 146 Actions brought against the United States would be before a
WTO panel.147 If implemented, the resulting bilateral and regional agreements
would limit the conditions under which United States pharmaceutical companies'
patents could be broken in exchange for lucrative trade benefits.1 48 Negotiations
have begun with several nations in the heart of the fight against HIV/AIDS, in149
cluding Botswana, South Africa, and Thailand.
The United States argues that stronger patents will save lives by assuring pharmaceutical companies that their rights will be protected. 150 According to an assistant United States trade representative, "It is crucial to public health

. . .

to

promote the innovation of drugs and to make sure research and development of
drugs continues."' 151 Although the United States promises to exempt AIDS drugs
from tightened protections, the promise remains absent from the text of the
139 Id.

140 See Heritage Foundation, 2007 Index of Economic Freedom: Botswana, http://www.heritage.org/
index/country.cfm?id=Botswana [hereinafter 2007 Index] (stating that Botswana's economy is ranked the
38th freest economy in the world). This score, however, has fallen since 2006 when Botswana was
ranked 30th and the most free of Africa's economies. See South Africa economicallyfreer, International
Marketing Council of South Africa, available at http://www.southafrica.info/doing-business/economy/
fiscal-policies/freedom-090106.htm.
141 2007 Index, supra note 140.
142 Id.
143 Id.

144Anand Giridharadas, U.S. Pushes to Limit Generic Drug Rights, INT'L HERALD TRIm., Apr. 19,
2006, available at http://www.bilaterals.org/article.php3?id-article=4458.
145 Helen A. Christakos, WTO Panel Report On Section 110(5) of the U.S. Copyright Act, 17 BERKELEY TECH. L.J. 595, 597 (2002).
146

Id.

147 Id.

148 Giridharadas, supra note 144.
149 Id.
150 Id.
151 Id.
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agreement. 52 The new agreements would prolong patents beyond the twentyyear mark where the developing country shows "unreasonable delays" in approving a patent. 15 3 They would also require retesting of generics, exclude forced
competition of branded products with generics, and limit the situations under
which patents may be broken.' 54 All these measures threaten affordability as
well as the ability for the world's nations to operate cohesively to fight HIV/
AIDS. The carefully orchestrated
compromises of the TRIPS agreement could
55
therefore be rendered null.'

In hopes of taking advantage of compulsory licensing in the TRIPS agreement,
Canada took the opposite approach in May 2004.156 Passing the Jean Chr6tien
Pledge to Africa Act (later renamed Canada's Access to Medicines Regime),
Canada is aiming to compel its pharmaceutical companies to offer some patented
drugs to generic producers. 157 The act requires that impoverished countries first
request such drugs, and then that generic producers contract to charge the countries only 25% of the cost of the brand-name counterpart.1 58 Generic drugs, however, have not reached poor countries under the act because negotiations between
159
patent holders and the generic producers proved difficult and unsuccessful.
60
Accordingly, the forced-agreement attempt utterly failed.
V.

Continued Compromise

The need for price-effective drugs will mostly likely become more urgent in
the near future. 16 Many successful HIV/AIDS programs have been effective
because of the lower cost of generic drugs. 162 "Most AIDS patients eventually
need to switch to second-line treatment because of the side-effects and drug resistance." 16 3 For example, one new antiretroviral combination therapy does not
need refrigeration and would be useful in Botswana, where as recently as 2002,
152 Id.
153 Id.
154 Id.

155 See Sherman & Oakley, supra note 44, at 362.
156 Canada Breaks Pledge, supra note 124.
157 Id.
158 Id.
159 Id.

160 See id.
161 Jacqui Wise, Access to AIDS Medicines Stumbles on Trade Rules, Bulletin of the World Health
Organization (May 1, 2006), available at http://www.who.int/bulletin/volumes/84/5/newsIO506/en/index.html [hereinafter Wise] (explaining that although first-line antiretrovirals are available as inexpensive generics, patients will eventually need to switch to second-line antiretrovirals which are less widely
available at affordable prices).
162 Id.
163

Id.
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only 24% of households had access to electricity. 164 However, according to
65
Medecins Sans Frontieres, this drug is not available in Africa at all.'
In addition to health conditions, social, economic, and psychological problems
66
threaten to become much worse before the HIV/AIDS epidemic subsides. 1
The impact of AIDS is still not fully understood, particularly when the
long term is considered. The epidemic comes in successive waves, with
the first wave being HIV infection, followed several years later by a wave
of opportunistic
diseases, and later still by a wave of AIDS illness and
167
then death.
Botswana has not yet been hit by the peak of the third wave, and has not ad68
vanced very far into the fourth wave of illness and death.
Yet hope is prompted by falling death and infection rates. 169 Additionally,
Botswana has been successful in complying with TRIPS obligations while maintaining the use of flexibilities inherent in the agreement; this balance included the
use of compulsory licenses.' 70 Its antiretroviral therapy program has been highly
successful and is a model for all developing countries dealing with the threat of
HIV/AIDS.1 7 1 Forcing negotiations between pharmaceutical manufacturers does
not work, as firms have no incentive to enter into unprofitable contracts. 7 2 On
the other hand, circumventing the flexibilities and compromises inherent in
TRIPS threatens the ability of developing nations to protect property rights while
serving their citizens in emergency and epidemic situations. 73 Such actions
would threaten the very "broad framework" for regulation of world trade, as op74
portunities for negotiation and compromise would be destroyed.
The use of TRIPS flexibilities in Botswana could be the answer to ensuring
such drugs continue to reach the hands of needy citizens. 17 5 Botswana shows
that participation in the world market and participation in TRIPS need not result
in dismissing health and other human rights concerns. This model, therefore, can
serve to aid other nations in battling life-threatening illness while maintaining a
growing economy. After all, Botswana will provide many heralded opportunities
164 Id. Helio International, 2002 Energy and Sustainable Development in Botswana, http://www.
helio-international.org/reports/2002/botswana.cfm.
165 Wise, supra note 161.
166

UNAIDS Impact, supra note 28, at 80-81.

167

Id. at 80.

168 Id. (explaining that none of the highly affected countries in Africa have hit the peak of the third

wave).
169 See Canada Breaks Pledge, supra note 124. This hope is evidenced by the fact that AIDS related
deaths dropped by nearly 50% between 2003 and 2005. Id. Such deaths fell from 33,000 to 18,000. Id.
170 Trade and Children's Rights, supra note 2,
9.
171

See Trade and Children's Rights, supra note 2,

172

See Canada Breaks Pledge, supra note 124.

6.

173 See Giridharadas, supra note 144.
174 Id.
175
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for both medical and economic researchers 76 as the HIV/AIDS epidemic carries
out its course. Secure investments by private medical companies can provide a
plethora of information regarding the disease. Resulting pharmaceutical developments could help patients and drug companies throughout the world fight and
eliminate the disease.
All such possibilities, however, depend upon the protection of invaluable intellectual property rights. Secure intellectual property rights lead to better developments in healthcare, which leads to a stronger economy. Botswana has shown
the world that human rights and economic concerns are not independent; rather
both objectives can be obtained in building a stronger, healthier nation.

176

See Shapiro & Hasset, supra note 13, at 15-16; Fayerman, supra note 49, at 268.
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